Skip to main content

Aeterna Zentaris Value Stock - Dividend - Research Selection

Aeterna Zentaris

ISIN: CA0079754028, WKN: A1439Z

Market price date: 21.05.2021
Market price: 1,07 USD

Aeterna Zentaris Fundamental data and company key figures of the share

Annual reports in USD
Key figures 05-04-2021
Cash flow
Net operating cash flow -5.540.000
Capital Expenditures -1
Free cash flow -5.540.001
Balance sheet
Total Equity 17.000.000
Liabilities & Shareholders equity 47.000.000
Income statement
Net income -6.860.000
Eps (diluted) -0,170
Diluted shares outstanding 41.080.000
Net sales/revenue 4.900.000

Fundamental ratios calculated on: 21-05-2021

Key figures 21-05-2021
Cash flow
P/C -7,56
P/FC -7,56
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization41.901.600,00 USD
Raw Data SourceIFRS in Millionen USD
Stock Split2015-11-20,1.0000/100.0000; 2012-10-05,1.0000/6.0000

Description of the company

Aeterna Zentaris Inc. is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,